ClinicalTrials.gg
CompletedNCT02699840Updated Apr 25, 2022

Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation

An observational study in Meningitis, Meningococcal Meningitis and Meningococcal Infections, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 1 site in Russian Federation. Open to participants aged 2 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-25.

Primary conditionMeningitis, MeningococcalRegistry: MeningitisReclassifiedWhy we changed it
Registry
Meningitis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Meningitis, Meningococcal
Why
  1. The study's listed conditions name Meningitis, Meningococcal, a narrower term within Meningitis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
2 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Meningitis, Meningococcal by Sanofi — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Sanofi.

Started
2016
with 6 others
Observational
Only one
of the 24
Registered
13th of 24
by date

Among the 24 studies in Meningitis, Meningococcal by Sanofi, this one is one of 7 that started in 2016, is the only observational one, and was the 13th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

None of the 24 studies in Meningitis, Meningococcal by Sanofi is open now. The open studies under Meningitis, Meningococcal, anywhere →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 2 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies in Meningitis, Meningococcal by Sanofi as a file.
02

Study summary

The aim of this study is to generate local data on the safety of Menactra® in individuals 2 to 55 years of age in the Russian Federation.

Primary Objective:

  • To describe the safety profile after 1 dose of Menactra® administered in individuals 2-55 years of age under standard health care practices.
Read the detailed description

Participants will be enrolled after receipt of one dose of Menactra® during a routine health care visit. They will be monitored for safety throughout the study.

03

Conditions studied

  • Meningitis
  • Meningococcal Meningitis
  • Meningococcal Infections

Browse trials for

Keywords

  • Meningitis
  • Meningococcal Meningitis
  • Meningococcal Infections
  • Menactra®
  • Meningococcal Vaccine
04

In context

Meningitis, Meningococcal Reclassified

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

This study's enrollment of 100 is below the median of 180 across 11 observational studies indexed under Meningitis, Meningococcal.

Browse Meningitis, Meningococcal studies →

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Compared within Meningitis, Meningococcal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Meningitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
2 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants aged 2 to 55 years will be enrolled after receipt of one dose of Menactra® during a routine health care visit.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 2 through 55 years on the day of enrollment "2 through 55 years" means from the day of the 2nd birthday to the day before the 56th birthday
  • For adults (18-55 years old) form has been signed and dated by the participant.
  • For minors: Informed consent form has been signed and dated by the parent. In addition, in accordance with the Institution Ethics Committee/Institution Review Board requirements and as appropriate for the age of the participant:
  • participants aged 14 to 17 years are required to sign and date the informed consent form,
  • participants aged 10 to 13 years are required to sign and date the assent form,
  • for participants under 10 years, consent may be asked orally according to participant's age and ability for understanding
  • Receipt of one dose of Menactra® on the day of inclusion and prior to enrollment into the study, in routine practice according to the approved local product insert.

Exclusion criteria

Exclusion Criteria:

  • Participation at the time of study enrollment (or in the 4 weeks preceding the enrollment) or planned participation during the present study period in a clinical study investigating a vaccine, drug, medical device, or medical procedure.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (actual)
Patient registry
No

Groups and cohorts

  • Menactra Study Group 1

    Participant aged 2 through 11 years at vaccination

    Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

  • Menactra Study Group 2

    Participant aged 12 through 17 years at vaccination

    Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

  • Menactra Study Group 3

    Participant aged 18 through 55 years at vaccination

    Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Interventions

  • BiologicalMeningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

    No vaccine will be provided as part of this study

    Also known as: Menactra®

  • BiologicalMeningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

    No vaccine will be provided as part of this study

    Also known as: Menactra®

  • BiologicalMeningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

    No vaccine will be provided as part of this study

    Also known as: Menactra®

07

What researchers measure

Primary outcomes

  1. Number of participants reporting solicited injection site and systemic reactions after a single dose of Menactra® vaccine

    Solicited injection site: Pain, Erythema and Swelling, Solicited systemic: Fever (Temperature), Headache, Malaise and Myalgia

    Time frame: Day 0 to Day 7 post-vaccination

Secondary outcomes

  1. Number of participants reporting unsolicited adverse events and serious adverse events after a single dose of Menactra® vaccine

    Time frame: Day 0 to Day 28 post-vaccination

08

Study locations

1 site
  • Moscow, Russian Federation
09

References and documents

Related links

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2016
First posted
Mar 4, 2016
Start
Feb 2016
Primary completionActual
Jul 25, 2016
CompletionActual
Jul 25, 2016
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02699840
Responsible party
Sponsor
First posted
Mar 4, 2016
Start date
Feb 2016
Primary completion
Jul 25, 2016
Completion
Jul 25, 2016
Last update
Apr 25, 2022

Study contacts

Medical Director
study director · Sanofi Pasteur Russia

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion